Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.
You may also be interested in...
No Laughing Matter: Avanir Resubmits Neurodex NDA
The firm is requesting priority review for involuntary emotional expression disorder.
No Laughing Matter: Avanir Resubmits Neurodex NDA
The firm is requesting priority review for involuntary emotional expression disorder.
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.